Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02346955 |
| Title | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ISR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Call for Information (Investigational Site 0003) | Los Angeles | California | 90095 | United States | Details | |
| Call for Information (Investigational Site 0004) | New Haven | Connecticut | 06513 | United States | Details | |
| Merck Sharp & Dohme Co. Ltd. | Hod Hasharon | Israel | Details |